Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Koji Tamura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2500-8810; OpenAlex author ID A5083943881. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
45
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: none · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: none · 2024: 1 paper

Papers 11

  1. MicroRNA-20a in extracellular vesicles derived from duodenal fluid is a possible biomarker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/deo2.333↗
  2. Serum Carboxypeptidase Activity and Genotype-Stratified CA19-9 to Detect Early-Stage Pancreatic Cancer. First author DOI 10.1016/j.cgh.2021.10.008↗
  3. Endoplasmic stress-inducing variants in carboxyl ester lipase and pancreatic cancer risk. Co-author DOI 10.1016/j.pan.2022.08.004↗
  4. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2019.10.036↗
  5. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.2017.72.3502↗
  6. Lack of association between the pancreatitis risk allele CEL-HYB and pancreatic cancer. Co-author DOI 10.18632/oncotarget.15137↗
  7. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000258↗
  8. Predictors and Diagnostic Strategies for Early-Stage Pancreatic Ductal Adenocarcinoma: A Retrospective Study. Co-author DOI 10.1097/mpa.0000000000000393↗
  9. Role of ERCP in the era of EUS-FNA for preoperative cytological confirmation of resectable pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00595-014-0845-0↗
  10. Intraoperative irrigation cytology of the remnant pancreas to detect remnant distinct pancreatic ductal adenocarcinoma in patients with intraductal papillary m… Co-author DOI 10.1016/j.surg.2013.06.059↗
  11. Unresectable pancreatic ductal adenocarcinoma in the remnant pancreas diagnosed during every-6-month surveillance after resection of branch duct intraductal pa… Co-author DOI 10.6092/1590-8577/1494↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Goggins · 5 shared papers, 2017–2022 · strength 0.49
  2. Jin Peng He · 4 shared papers, 2017–2022 · strength 0.43
  3. Toshiya Abe · 3 shared papers, 2020–2024 · strength 0.40
  4. Marcia Irene Canto · 3 shared papers, 2020–2022 · strength 0.38
  5. Richard Andrew Burkhart · 3 shared papers, 2020–2022 · strength 0.38
  6. Yoshinao Oda · 6 shared papers, 2013–2024 · strength 0.36
  7. Noboru Ideno · 6 shared papers, 2013–2024 · strength 0.36
  8. Takao Ohtsuka · 6 shared papers, 2013–2024 · strength 0.36
  9. Alison P. Klein · 4 shared papers, 2017–2022 · strength 0.35
  10. Takeichi Yoshida · 2 shared papers, 2022 · strength 0.29
  11. Kenoki Ohuchida · 2 shared papers, 2015–2024 · strength 0.22
  12. Nicholas Jason Roberts · 2 shared papers, 2017–2022 · strength 0.20
  13. Ralph H. Hruban · 3 shared papers, 2017–2020 · strength 0.20
  14. Anne M. Macgregor-Das · 2 shared papers, 2017–2022 · strength 0.19
  15. Junji Ueda · 5 shared papers, 2013–2015 · strength 0.18
  16. Masao Tanaka · 5 shared papers, 2013–2015 · strength 0.18
  17. Masahiro Yamamoto · 1 shared paper, 2024 · strength 0.17
  18. So Nakamura · 1 shared paper, 2024 · strength 0.17
  19. Masafumi Nakamura · 1 shared paper, 2024 · strength 0.17
  20. Kohei Nakata · 1 shared paper, 2024 · strength 0.17
  21. Naoki Ikenaga · 1 shared paper, 2024 · strength 0.17
  22. Takashi Taniguchi · 1 shared paper, 2024 · strength 0.17
  23. Makoto Kawamoto · 1 shared paper, 2022 · strength 0.15
  24. Koji Shindo · 3 shared papers, 2013–2017 · strength 0.14
  25. Amanda L. Blackford · 1 shared paper, 2022 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.